000			01659na a2200241 4500
003			H12O
005			20180417112621.0
008			130622s2012 xxx||||| |||| 00| 0 eng d
040			_cH12O
041			_aeng
100			_aPaz-Ares Rodríguez, Luis _91811 _eOncología Médica
100			_aSánchez, José Miguel _92085 _eOncología Médica
245			_aErlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. _h[artículo]
260			_bThe Lancet Oncology, _c2012
300			_a13(3):239-46.
500			_aFormato Vancouver: Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012 Mar;13(3):239-46.
501			_aPMID: 22285168
504			_aContiene 24 referencias
520			_aErlotinib has been shown to improve progression-free survival compared with chemotherapy when given as first-line treatment for Asian patients with non-small-cell lung cancer (NSCLC) with activating EGFR mutations. We aimed to assess the safety and efficacy of erlotinib compared with standard chemotherapy for first-line treatment of European patients with advanced EGFR-mutation positive NSCLC.
710			_9303 _aServicio de Oncología Médica
856			_uhttp://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc/6/pc6931.pdf _ySolicitar documento
942			_n0 _2ddc _cART
999			_c6931 _d6931